Skip to main content

Table 2 Overall response rate

From: NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

RESPONSE RATE
RC 2 (4.8 %)
RP 13 (31.7 %)
ORR 15 (36.6 %)
SD 14 (34.2 %)
DCR 26 (70.7)
PD 12 (29.3)
CA19.9 > 50 % reduction 17 (41.5 %)
\